

Industry Call for Opportunities

Cell and Gene-based Treatments for Canine Diabetes

A global animal health company is seeking research and technologies related to cell and gene-based treatments for canine type I and II diabetes. The team are looking to develop novel treatments for dogs, but research in humans is of interest at this stage. The research should relate to simulating insulin-producing cells in order to stabilise and maintain appropriate blood glucose levels. Treatments should aim to stabilise glucose for at least 3-6 months, preferably more. Our client is particularly interested in validated research ready for further development e.g. manufacturing or clinical testing.



Approaches of Interest:

- · Allogenic and heterogeneous cell therapies are prioritised, however autologous is also of interest
- Gene therapies, including ex vivo genetic modification and viral gene therapies
- · Less invasive treatments with minimal number of interventional procedures are preferred
- · Research with validation in humans is of interest if it has the potential to be applied to canine diabetes
- Novel treatment platforms from other disease areas that have potential to be applied to diabetes may also be considered

Developmental Stages of Interest:

- Opportunities at basic research phase to clinical phase I are within scope, with a preference for later stage research with canine validation data
- Opportunities with *in vivo* validation are of highest interest, although opportunities with *in vitro* validation will still be considered
- · Opportunities with procedures that have reproducible methods to obtain and grow the cell therapies


Submission Information:

Submission of one page, 200-300 word briefs are encouraged, along with any optional supplementary information e.g. relevant publications. Intellectual property status of the research should be included where relevant. In submitting to this campaign, you confirm that your submission contains only non-confidential information. Identified risks and mitigation plans for the proposed approach are highly valued.

Opportunity for Collaboration:

Our client is open to a range of collaboration scenarios, with the most appropriate path determined by the quality and needs of the opportunity submitted. Example outcomes include licensing of assets, partnering on development and/or manufacture of a treatment, research collaborations and project funding. Outcomes will be determined on a case by case basis.

Opportunities sought



Academics and expertise

Centres of excellence

Research projects

Spinout companies

Submissions

Please submit relevant, non-confidential opportunities online via: <u>discover.in-part.com</u>

Deadline: 30th January 2023 - 11:59 pm GMT

Have any questions?
Contact our team at discover@in-part.co.uk